Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov-Dec;4(6):359-65.
doi: 10.4161/isl.23345. Epub 2012 Nov 1.

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin

Affiliations
Review

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin

Xiaoquan Xiong et al. Islets. 2012 Nov-Dec.

Abstract

During the past two decades, the exploration of function of two incretin hormones, namely glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), has led to the development of two categories of novel therapeutic agents for diabetes and its complications, known as GLP-1 receptor (GLP-1R) agonists and DPP-IV inhibitors. Mechanisms underlying the function of GLP-1, however, still need to be further explored. GLP-1 not only functions as an incretin hormone in stimulating insulin secretion in response to nutritional, hormonal and neuronal stimulations, but also acts as an "insulin-like" factor in β-cell and extra-pancreatic organs. In addition to these insulinotropic and insulinomimetic effects, GLP-1 was shown to exert its protective effect in β-cell by repressing the expression of TxNIP, a mediator of glucolipotoxicity. A number of recent studies have shown that the Wnt signaling pathway effector, the bipartite transcription factor β-catenin/TCF, controls not only the production of GLP-1, but also the function of GLP-1. Furthermore, previously assumed "degradation" products of GLP-1(7-36)amide, including GLP-1(9-36)amide and GLP-1(28-36)amide, have been shown to exert beneficial effect in pancreas and extra-pancreatic tissues or cell lineages. Here we summarized our current knowledge on the metabolic, proliferative and protective effects of GLP-1(7-36)amide and its cleavage fragments, mainly focusing on pancreatic β-cells and the involvement of the Wnt signaling pathway effector β-catenin.

Keywords: GLP-1; TCF7L2; TxNIP; Wnt signaling pathway; β-catenin.

PubMed Disclaimer

Figures

None
Figure 1. Proglucagon and its cleavage products. (A) The gcg gene encode proglucagon, a pro-hormone with 160 amino acid residues (top panel). This pro-hormone contains three PC2 and four PC1/3 cleavage sites. A schematic presentation of the cleavage products of proglucagon in the pancreas (middle panel) and in the intestine and brain (bottom panel). (B) Amino acid sequences of GLP-1(7–36)amide, GLP-1(9–36)amide and GLP-1(28–36)amide. The cleavage sites for DPP-IV and NEP24.11 are indicated with arrows. GRPP, glycentin related polypeptide; IP1 and IP2, intervening peptide 1 and 2; MPGF, major proglucagon fragment; DPP-IV, dipeptidyl peptidase-4; NEP 24.11, neutral endopeptidase 24.11.
None
Figure 2. An illustration of the Wnt signaling pathway. Without Wnt ligand stimulation, β-cat is trapped within the “destruction complex,” phosphorylated by the protein kinase GSK-3 and CK-1α at Ser33 and adjacent Ser positions, and subsequently degraded by proteasome (left). Following Wnt ligand stimulation and Dishvelled (Dvl) activation, β-cat escapes the trapping, enters the nucleus and forms the bipartite transcription factor cat/TCF, which leads to the stimulation of Wnt target gene expression (middle). GLP-1 was shown to activate cAMP-dependent protein kinase A (PKA), and stimulate β-cat Ser675 phosphorylation, which is positively associated with its nuclear translocation and Wnt target gene expression (right).
None
Figure 3. Summary of insulinotropic and insulinomimetic effects of GLP-1 and its cleavage products in pancreatic β-cells. The cleavage of GLP-1(7–36)amide (defined as 7–36amide) by DPP-IV leads to the production of GLP-1(9–36)amide (defined as 9–36amide). The cleavage by NEP 24.11 leads to the production of GLP-1 (28–36)amide (defined as 28–36amide). GLP-1R mediates the insulinotropic effect of 7–36amide and GLP-1R agonists, such as exendin-4, involving both cAMP/PKA and cAMP/Epac. PKA can activate β-cat via increasing its Ser675 phosphorylation, which is at least partially responsible for the insulinomimetic effect of GLP-1. Whether 28–36amide exerts its insulinomimetic effect in pancreatic β-cells via a yet to be identified receptor, or a receptor independent mechanism remain to be further investigated. Whether or not 28–36amide exerts its insulinomimetic effect via stimulating β-cat Ser675 phosphorylation is also worth to be further examined.

Similar articles

Cited by

References

    1. Jin T. Mechanisms underlying proglucagon gene expression. J Endocrinol. 2008;198:17–28. doi: 10.1677/JOE-08-0085. - DOI - PubMed
    1. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876–913. doi: 10.1210/er.20.6.876. - DOI - PubMed
    1. Holst JJ, Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes. 2004;53(Suppl 3):S197–204. doi: 10.2337/diabetes.53.suppl_3.S197. - DOI - PubMed
    1. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006;49:253–60. doi: 10.1007/s00125-005-0107-1. - DOI - PubMed
    1. Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology. 2010;151:1520–31. doi: 10.1210/en.2009-1197. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources